Once again, after the outbreak in 2022, the Monkeypox virus (MPXV) is rapidly spreading in the central and western region of Africa.
Last Wednesday 14th of August 2024, the World Health Organisation (WHO) determined that this new outbreak of Monkeypox constitutes a public health emergency of international concern (PHEIC). During the first half of 2024, reported cases have reached the values reported in the whole last year 2023.
Monkeypox virus transmits between humans through close contact with lesions, body fluids, respiratory droplets or contaminated materials. It can also be transmitted or from animals to humans through contact with live animals or consumption of contaminated bushmeat.
The GPS™ MPXV dtec-qPCR assay has been designed following phylogenetic criteria to recognise both clade I and clade II of the virus, and is therefore expected to detect all emerging variants.
In the following link, you will find a scientific publication presenting the data obtained from the validations of the MPXV dtec-qPCR assay, including the diagnostic validation carried out by the reference laboratory Instituto de Salud Carlos III with 40 clinical samples.
The assay developed by GPS™ demonstrated 100% diagnostic specificity and sensitivity, as well as showing the highest sensitivity (low limit of detection) compared to assays from other commercial providers.
Despite the absence of sequences identified as belonging to clade Ib of the MPXV in the databases, a thorough review has confirmed that the design is specific to all new Monkeypox virus sequences published until 2024.
Click here to view the product description
Keep up with mpox updates on our LinkedIn profile.
